MiR-29c regulates the expression of miR-34c and miR-449a by targeting DNA methyltransferase 3a and 3b in nasopharyngeal carcinoma

Man Niu, Dan Gao, Qiuyuan Wen, Pingpin Wei, Suming Pan, Cijun Shuai, Huiling Ma, Juanjuan Xiang, Zheng Li, Songqing Fan, Guiyuan Li and Shuping Peng

Abstract

Background: Nasopharyngeal carcinoma (NPC) is prevalent in South East Asia and Southern China particularly. Despite the reported 5-year survival ratio is relative higher than other deadly cancers such as liver, renal, pancreas cancer, the lethality is characterized by high metastatic potential in the early stage and high recurrence rate after radiation treatment. MicroRNA-29c was found to be down-regulated in the serum as well as in the tissue of nasopharyngeal carcinoma tissue.

Methods: In this study, we found accidentally that the transfection of pre-miR-29c or miR-29c mimics significantly increases the expression level of miR-34c and miR-449a but doesn’t affect that of miR-222 using real-time quantitative PCR in nasopharyngeal carcinoma cell lines. To explore the molecular mechanism of the regulatory role, the cells are treated with 5-Aza-2-deoxycytidine (5-Aza-CdR) treatment and the level of miR-34c and miR-449a but not miR-222 accumulated by the treatment. DNA methyltransferase 3a, 3b are down-regulated by the 5-Aza-CdR treatment with western blot and real-time quantitative PCR.

Results: We found that pre-miR-29c or miR-29c mimics significantly increases the expression level of miR-34c and miR-449a. We further found DNA methyltransferase 3a and 3b are the target gene of miR-29c. Restoration of miR-29c in NPC cells down-regulated DNA methyltransferase 3a, 3b, but not DNA methyltransferase T1.

Conclusions: The regulation of miR-29c/DNMTs/miR-34c\449a is an important molecular axis of NPC development and targeting DNMTs or restoring of miR-29c might be a promising therapy strategy for the prevention of NPC.

Keywords: Nasopharyngeal carcinoma, miR-29c, miR-34c, miR-449a, DNA methyltransferase

Background

Nasopharyngeal carcinoma (NPC) is prevalent in South East Asia and Southern China particularly. Despite the reported 5-year survival ratio is relative higher than other deadly cancer such as liver, renal, pancreas cancer, the lethality is characterized by high metastasis in the early stage and high recurrence rate after radiation treatment. Due to the secluded anatomical sites, early symptom of patients is not typical, 80 - 90 % patients with NPC are diagnosed until the late advanced stage. EB virus infection, genetic factors, environmental and diet factor are widely recognized to be associated with the etiology of NPC carcinogenesis [1, 2]. However, recent studies have found that genome-wide epigenetic modifications in tumor associated gene are also involved in this process [3–5].

Epigenetic modification refers to the changes in gene expression, but not a genetic change in the DNA sequence, and can be stably transmitted through meiosis in the process of growth and cell proliferation.

© 2016 Niu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Epigenetic factor has been proved to play an important role in the carcinogenesis and development of nasopharyngeal carcinoma (NPC). Detection of epigenetic modifications can serve as molecular context of NPC and it is advantageous in the prognosis of NPC. The regulation of the epigenetic modification is reversible so that different intervention measures in epigenetic aspect may be used as a novel strategy to treat NPC, as well as the development of novel NPC radiotherapy sensitizing agent and novel drugs.

MicroRNAs (miRNAs), small non-coding RNA, exist in many organisms and play a important role in the regulation of protein expression by binding the 3′-untranslated region (3-UTR) of their target mRNAs through completely or incompletely complementary seed sequences and assembled in RNA-induced silencing complex (RISC), mediating the degradation of mRNA or the blockade of the translation of encoded protein. Abnormal expression of miRNAs has been demonstrated in most tumor types including NPC [6–8]. In previous studies of our laboratory as well as other research groups, miR-29c was found to be down-regulated in the serum of NPC patients [9–12], while, the effect of miR-29c and the pathways in which miR-29c works during the development and progression of NPC are not well defined. Therefore, in this study, we investigated the biological functions and molecular mechanism of miR-29c in NPC, which may help to further elucidate the roles of miRNAs in the development of NPC and provide a novel candidate target for therapeutic strategies for NPC.

In this study, we accidently found that pre-miR-29c transfection in nasopharyngeal carcinoma increased the expression of miR-34c and miR-449a. In order to seek for the molecular mechanism of this event, we hypothesized that miR-29c down-regulated DNA methyltransferases (DNMTs), which catalyze the addition of a methyl group to the cytosine residue of CpG nucleotides. In NPC tissue, the down-regulation of miR-29c leads to the high level of DNMTs, which further promote the methylation of the CpG islands of tumor suppressors such as miR-34c and miR-449a. Our experimental data showed that epigenetic modifications of miR-34c and miR-449a are affected by the DNMTs, especially DNMT3a and DNMT3b.

Methods
Cells and cell culture
Human nasopharyngeal carcinoma cell lines, HNE-1, CNE-2, C666-1 and the immortalized human nasopharyngeal epithelial cell line NP69, which is immortalized with an SV40 T-antigen, was a kind gift from Professor Sai Wah Tsao of the Department of Anatomy, University of Hong Kong, China, and was maintained in keratinocyte-serum free medium (Invitrogen, Carlsbad, CA, USA) with the addition of growth factor supplements (Life Technologies, Gaithersburg, MD, USA) [15].

Drug treatment
Cells were incubated with the 5-Aza-2′-deoxycytidine (5-Aza-CdR) (10 μM) (Sigma, MO, USA) for 96 h, with or without Trichostatin A (TSA) (10 μM) (Sigma, MO, USA) or TSA alone for the last 24 h. 5-Aza-CdR is methylation methyltransferase inhibitor, an epigenetic modifier that inhibits DNA methyltransferase activity which results in DNA demethylation (hypomethylation) and gene activation by remodeling “opening” chromatin. Genes are synergistically reactivated when the demethylation is combined with histone hyperacetylation. Trichostatin A is a histone deacetylase inhibitor.

Pre-miRNA constructs and miRNA mimics transfection
Pre-miR-29c or scramble cDNA together with restriction enzyme sites were inserted into pSuper vector (OligoEngine, WA, USA) and transformed into E. coli JM109. The clones with positive inserts were subjected to the plasmids extraction and confirmed to be correct by DNA sequencing. Cells were seeded in 6-well dish (4*10⁶ cells/well) the day before and were transfected with scramble pSuper or pre-miR-29c/pSuper with Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. Forty-eight hours after the transfection, the expression of miR-29c, miR-34b, miR-449a was detected by real-time PCR, and the expression of DNMT3a, 3b, T1 was tested by real-time PCR and Western blotting.

Quantitative real time PCR (qRT-PCR)
Total RNA was extracted using miRNeasy Mini kit (Qiagen, Germany) according to the manufacturer's instructions. For miRNA expression analysis, cDNA was synthesized using miScript II RT Kit (Qiagen, Germany). A PCR analysis was performed using miScript SYBR Green PCR Kit (Qiagen, Germany). Hsa-miR-29c-1 miScript Primer, Hsa-miR-34c-1 miScript Primer, Hsa-miR-222-1, Hsa-miR-449a-1 miScript Primer (Qiagen, Germany) were used and RNU6 (Qiagen, Germany) acted as an internal control. The PCR cycle parameters were as follows: 95 °C for 15 min, 39 cycles of denaturation at 95 °C for 15 s, annealing at 50 °C for 30 s, and extension at 70 °C for 30s. For mRNA expression analysis, cDNA was synthesized using cDNA reverse transcription kit (Thermo Fisher Scientific, MA, USA) and a PCR analysis was performed using Quantifast SYBR Green PCR Kit following the manufacturer's instructions.
The PCR cycle parameters were as follows: denaturation at 95 °C for 5 min, 39 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. DNMT3a, 5′ primer (5′-CCGGA ACATT GAGA CATCT-3′) and 3′ Primer (5′-CAGCAGATGGTGACAG TAGGA-3′); DNMT3b, 5′ primer (5′-GGAGA CT CAT TGGAG GACCA) and 3′ Primer (CTCGG CTCTG ATCTT CATCTC-3′); DNMT1, 5′ primer (5′-GAGGCA CAGATGCTGACAAA-3′) and 3′ primer (5′-TGCCT TAAACACCACCTTCA-3′). β-actin, 5′ primer(5′-CCTAGCATGGAGTGGT-3′) and 3′ Primer (5′-CTGA GCCATAGAGGGGACG -3′), β-actin acted as internal control. These experiments were performed according to the manufacturer's protocol of Bio-Rad CFX96 System.

**Western blot analysis**

Cells were harvested at the indicated time and rinsed twice with cold PBS. Cell extracts were prepared with lysis buffer containing 50 mM Tris–HCl, pH7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton, 1 mM phenyl-methylsulfonyl fluoride, and protease inhibitor mixture(-Roche, USA) for 20 min on ice. Lysates were cleared by centrifugation at 14,000 rpm at 4 °C for 10 min. Supernatants were collected, and protein concentrations were determined by Pierce BCA Protein Assay (Pierce, USA). The proteins samples were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) in 10 % (wt/vol) polyacrylamide gels and transferred to nitrocellulose membrane (Millipore, USA). After blocking with 5 % non-fat dry milk for 1 h at room temperature, the membrane was incubated with the primary antibodies in 5 % non-fat dry milk overnight at 4 - 8 °C. The following antibodies were utilized: anti-DNMT3a mouse polyclonal antibody (Santa Cruz, USA), anti-DNMT3b rabbit polyclonal antibody (Anbo, USA), anti-DNMT1 rabbit polyclonal antibody (Santa Cruz, USA), anti-β-actin mouse polyclonal antibody (Abclonal, USA). Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antimouse antibody or anti-rabbit antibody (CST, USA). After additional washes with phosphate-buffered saline, the band signals were visualized and quantified with chemiluminescence kit (AidLab, China).

**Immunohistochemical staining and evaluation**

The paraffin sections of NPC tissue microarray were collected from the patients of the Pathology Department of the Second Xiangya Hospital of Central South University between 2007 - 2014. The tissue slides were heated 65 °C for 1 h, and deparaffinized in xylene and rehydrated through graded alcohols (100, 90, 70 and 50 % alcohol; 5 min for each). For antigen retrieval, tissue slides were incubated in sodium citrate buffer (0.01 M, pH 6.0) for 20 min in a household Pressure cooker. After cooling to room temperature, the slides were washed in PBS (150 mM sodium chloride, 150 mM sodium phosphate, pH 7.2). The endogenous peroxidase activity was removed by incubating with 3 % hydrogen peroxide for 10 min and was blocked in normal goat serum (Maixin, China) for 30 min. The primary antibodies (anti-DNMT1, anti-DNMT3a and anti-DNMT3b) were applied at 4 °C overnight. Polymerized HRP and anti-rabbit IgG (Maixin, China) were added according to the manufacturer’s instructions. A color reaction was developed using DAB Color Developing Reagent Kit (Boster, China), and all of the slides were counterstained with hematoxylin staining kit. Negative control slides were included in the experiment. The immune histochemical staining of these sections was scored microscopically (Olympus, Japan) at × 400 magnification in all of the available tumor cells or epithelial cells meeting the typical morphological criteria by 3 pathologists using the qualitative scale that is described in the literature. The number of cells staining was scored as 0 (no staining), 1 (1-10 %), 2 (11-50 %), 3 (51-75 %), or 4 (76-100 %).

**Fig. 1** The expression of miR-29c is down-regulated in nasopharyngeal carcinoma cell lines and tissues. a Total RNA was extracted from normal nasopharyngeal epithelium cells (NP69) and NPC cell lines (HNE1, HNE2, CNE2, C666-1, HK-1) and reversely transcribed into cDNA. Q-PCR was performed and analyzed for the expression level of miR-29c normalized by RNAU6. b The same method and protocol was performed from NPC tissue and reversely transcribed, Q-PCR was performed and analyzed. N: normal nasopharyngeal epithelium tissue, 2, 3, 4 were presented for Clinical Stage 2, 3, 4, M was presented for the NPC tissue with metastasis. 30 samples were used, each group contains six samples.
1 + (<1/3 positive cells), 2 + (>1/3 and < 2/3 positive cells) and 3 + (>2/3 positive cells). The intensity of staining was scored from 1 + (weak) to 3 + (strong). The immune reactive score was categorized into three groups by comprehensive evaluation of the percentage of positive cells and staining intensity.

Results

Hsa-miR-29c is down-regulated in NPC cell lines and NPC tissues, correlated with clinical stage of NPC

To investigate our hypothesis, we first examined the expression of miR-29c in NP69, HNE-1, HNE2, CNE2, HK1, and C666-1 cells. As previously reported, miR-29c is relative high in normal nasopharyngeal epithelial cells (NP69), and low in NPC cell lines (HNE-1, CNE2, HK1, HNE2, C666-1) (Fig. 1a). In the tissues of NPC patients, snap-frozen NPC biopsies were obtained from NPC patients and normal healthy nasopharyngeal epithelial samples from biopsy-negative cases were used as control. The criteria of clinical staging of NPC samples were based on the 2008 staging system of NPC and AJCC staging system [16, 17]. Samples were first frozen-sectioned by using a LEICA CM 1900 cryomicrotome. 6 NPC samples in each clinical staging II ~ V were used (numbers I to IV) and control group. Samples were collected from the Second Xiangya Hospital affiliated by Central South University. The patients were informed about the sample collection and had signed informed consent forms. Collections and use of tissue samples were approved by the ethical review committees of Xiangya Second Hospital. Laser capture micro-dissection was used to separate the cancer tissues from the normal tissues [18].
contrast images were acquired using LEICA CTR 6500 microscope. Total RNA was extracted using Trizol® reagent (Invitrogen) from samples. Two hundred nanograms (200 ng) of total RNA from each sample were used for the follow-up microarray. As the result showed the expression level of miR-29c is negatively associated with clinical stage (Fig. 1b).

MiR-29c increases the expression level of miR-34b/c and miR-449a significantly

Pre-miR-29c cDNA or scramble DNA was inserted into pSuper vector and confirmed to be correct by sequencing. The constructs were transfected into nasopharyngeal carcinoma cell line HNE1 and CNE2 in which miR-29c expression is down-regulated. It is surprisingly found that the expression of miR-34c and miR-449a were increased, while that of miR-222 wasn’t altered (Fig. 2a and b). In mammalian genome, the miR-34 family (miR-34 s) consists of miR-34a, miR-34b and miR-34c. miR-34a localizes to chromosome 1p36, while miR-34b and miR-34c form a cluster and localize to chromosome 11q23. In additional experiments, miR-29c mimics and negative control reagents (Qiagen, German) were transfected into the cell lines, we got similar results (data not shown).

Mir-34c and miR-449a belong to miR-34 family which is found down-regulated in nasopharyngeal carcinoma and other cancers [18–21]. Expression of miR-34 family members were reported down-regulated in cancer cells by abnormal DNA methylation [21–28]. However, the molecular mechanism of miR-34c/miR-449a down-regulation in nasopharyngeal carcinoma is not clear. In order to explore whether the expression of miR-34c and 449a in nasopharyngeal carcinoma cells

Fig. 4 DNMT3a and 3b but not DNMT1 are down-regulated by pSuper-pre-miR-29c transfection. DNMT3a, 3b, 1 were predicted as tentative targeted genes of miR-29c. Cells were transformed with pre-miR-29c and cultured for 24 h for Q-PCR and western blots for 48 h. a, b Q-PCR analysis of DNMT3a, 3b, 1 regulated by miR-29c in HNE1 and CNE2. c Western blot analysis of DNMT3a, 3b and DNMT1 transfected with pre-miR-29c.

Fig. 5 MiR-29c inhibits the growth of nasopharyngeal carcinoma cells HNE1 and CNE2 by MTT assay. Cells were transformed with pre-miR-29c and cultured for 24 h. 5 × 10^4 cells were seeded into 96-well dish triplicately. 20ul MTT solution was added to each well and then 200ul DMSO was added to the well with cells. Read optical density at 490 nm and subtract background at 570 nm. The readout was recorded at 4 time points (24, 48, 72, 96, 120 h).
is regulated by epigenetic factors, the cells were treated with DNA methylation inhibitor, 5-Aza-2’-deoxycytidine (5-Aza-CdR), or/and histone deacetylase inhibitor, Trichostatin A (TSA). As expected, the expression of miR-34b/c and 449a is increased with the treatment of 5-Aza-CdR and that of miR-222 was not altered either in HNE1 and CNE2 (Fig. 3a and b). To update, there has no literatures indicating that miR-222 is regulated by epigenetic factors, which may explain the reason why miR-222 expression wasn’t affected by 5-Aza-CdR. Several software analysis also showed no typical CpG islands exists in the genomics sequences of miR-222 or miR-29c. DNA methyltransferase 3a and 3b expression were inhibited by 5-Aza-CdR treatment, while DNA methyltransferase T1 seemed not to be altered (Fig. 3c and d).

DNMT3a and 3b are direct targets of miR-29c

In order to determine whether miR-29c regulate the miR-34c and 449a through down-regulating the DNMT3a and DNMT3a, pre-miR-29c constructs or hsa-29c mimics and scramble DNA were transfected into HNE1 and CNE2 cell line, respectively. It was found that the expression of DNMT3a and DNMT3b were decreased significantly with the transfection pre-miR-29c or hsa-29c mimics, but not altered with scramble constructs. However, the level of DNMT1 was not altered significantly (Fig. 4a, b and c). The miR-29 family members have intriguing complementarities to the 3’-UTRs of DNMT-3a and -3b, involved in DNA methylation. DNMT3a and 3b have been confirmed as direct targets of miR-29c in lung carcinoma, breast cancer, and cutaneous melanoma [29–32]. The expression of miR-29 family members are inversely correlated to DNMT-3a and -3b in lung cancer, directly targeting both DNMT3a and -3b [32–33].

**Table 1** Correlation between DNMT3a expression and clinicopathological characteristics of nasopharyngeal carcinoma

| Variable | No. of patients (n, %) | DNMT3a | Chi-squared test | P-value |
|----------|------------------------|--------|-----------------|--------|
| Age (years) | | | | |
| <45 | 25 | 22 (88) | 3 (12) | 0.0557 |
| >45 | 43 | 32 (74.4) | 11 (25.6) | |
| Gender | | | | |
| Male | 54 | 43 (79.6) | 11 (20.4) | 0.0652 |
| Female | 14 | 10 (71.4) | 4 (28.6) | |
| Stage | | | | |
| TNM I-II | 16 | 13 (81.2) | 3 (18.8) | 0.0012* |
| TNM III-IV | 39 | 27 (69.2) | 12 (30.8) | |
| Unknown | 13 | 10 (76.9) | 3 (32.1) | |

*p < 0.05 was significant statistically

**Table 2** Correlation between DNMT3b expression and clinicopathological characteristics of nasopharyngeal carcinoma

| Variable | No. of patients (n, %) | DNMT3b | Chi-squared test | P-value |
|----------|------------------------|--------|-----------------|--------|
| Age (years) | | | | |
| <45 | 40 | 33 (82.5) | 7 (17.5) | 0.5747 |
| >45 | 38 | 32 (84.2) | 6 (15.8) | |
| Gender | | | | |
| Male | 64 | 54 (84.4) | 10 (15.6) | 0.2127 |
| Female | 14 | 14 (100) | 0 | |
| Stage | | | | |
| TNM I | 19 | 13 (68.4) | 6 (31.6) | 0.3122 |
| TNM III-IV | 47 | 40 (85.1) | 7 (14.9) | |
| Unknown | 12 | 11 (91.7) | 1 (8.3) | |

**Table 3** Correlation between DNMT1 expression and clinicopathological characteristics of nasopharyngeal carcinoma

| Variable | No. of patients (n, %) | DNMT1 | Chi-squared test | P-value |
|----------|------------------------|--------|-----------------|--------|
| Age (years) | | | | |
| <45 | 29 | 21 (72.4) | 8 (27.6) | 0.7679 |
| >45 | 31 | 24 (77.4) | 7 (22.6) | |
| Gender | | | | |
| Male | 47 | 34 (72.3) | 13 (27.7) | 0.7638 |
| Female | 13 | 9 (69.2) | 4 (30.8) | |
| Stage | | | | |
| TNM I-II | 12 | 9 (75) | 3 (25) | 0.6202 |
| TNM III-IV | 38 | 25 (65.8) | 13 (34.2) | |
| Unknown | 10 | 9 (90) | 1 (10) | |

Expression of DNMT3a, 3b, T1 associated with prognosis of nasopharyngeal carcinoma

Based on microarray analysis in previous study it has been found that miR-29c,miR-34c, and miR-449a are down-regulated in NPC (data not shown). The target genes of miR-29c such as BCL2L2, HBEGF, HBP1, HSPG2, ITGB1, LAMC2, LTBR, MIB1, MLF1, MMP2,NDST1, SVEP1MCL-1,BCL-2, TIAM1 were up-regulated and miR-29c could sensitize NPC cells to ionizing radiation and cisplatin treatment by promoting apoptosis [10, 11, 18]. In our study, the recovery of miR-29c expression delayed the proliferation and growth of NPCs (Fig. 5a and b). We examined that DNMT3a, 3b, and T1 are strongly expressed in NPC tissues. The clinical information of the patients was listed in Tables 1, 2 and 3. DNMT3a, 3b, 1 expression...
is not associated with gender ($p = 0.0652, 0.2127, 0.7638$ respectively) or age ($p = 0.0557, 0.5747, 0.7679$, respectively). The expression of DNMT3a, but neither DNMT3b nor DNMT1 was associated with clinical stage of NPC ($p = 0.0012, p = 0.3122$ and $0.6202$ respectively). The representative images of positive and negative expression of DNMT3a, 3b and T1 are shown in Fig. 6a (a–i), 7A (a–i), 8A (a–i).

The score was evaluated by 3 experienced pathologists were analyzed with $\chi^2$ test. The expression of DNMT3a is negatively associated with 5-year survival time (log Rank $p = 0.0014$) and total survival time (Fig. 6B a–b), however, the expression of DNMT3b, DNMT1 are not significantly associated with 5-year survival time and total survival time (Fig. 7b a–b, Fig. 8b a–b).
Discussions
As well known, miRNAs play an important role in various cellular activities by regulating gene expression of their targets. Recent studies have shown that the expression of miRNA is regulated by epigenetic modifications by DNA methylation or histone modification. MiRNA also can be the key factor to regulate the levels of DNA methylation or histone modification which affect the expression level of other molecules. All these factors (extracellular signals, miRNAs, transcription factor, targeted gene) are the members of the vast gene expression regulatory networks. In cancer cells, the epigenetic modifications of miRNAs have been reported. Those miRNAs acting as tumor suppressor often were silenced by frequent hypermethylation or histone deacetylation. Furthermore, it shows tumor specialty. When treated with demethylating agent 5-aza-deoxycytidine (5-Aza-CdR) and histone deacetylase (4-Phenylbutyrie acid, PBA), the expression of 5 % miRNAs in bladder carcinoma cell line T24 increased by 3 folder than that.
of untreated. MiR-34c acts as a suppressor in many tumors. It’s down-regulated and the target genes DCBLD2, FOXN3, IKZF1, NPTN, PAFAH1B1, USP10, YY1, ARHGAPI, ARHGEF3, BCL11B, C16orf5, CNTNAP1, FOXD3, FUT8, IL6R, ITGB8, ITSN1, JAG1, MLL2, NDST1, NOTCH2, NPNT, PPFIA1, PTPRM, PVRL1, SERPINE1, VCL were up-regulated in NPC [18]. Single hyper methylation of CpG island in the promoter region of miR-34c gene repressed miR-34c expression by reducing DNA binding activities of Sp1 and promoted self-renewal and epithelial-mesenchymal transition of breast tumor-initiating cells [32]. Differential methylation of CpG islands neighboring the miR-34c promoter inhibited the expression of miR-34c in gastric cancer cell lines and in paclitaxel-resistant gastric cancer samples. MiR-34c was down-regulated and its target microtubule-associated protein tau (MAPT) protein expression was high. Over expression of miR-34c significantly down-regulated MAPT protein expression and increased the chemo sensitivity of paclitaxel-resistant gastric cancer cells [34]. Aberrant DNA methylation
of miR-34c was correlated with a high probability of recurrence and associated with poor overall survival and disease-free survival in non-small cell lung cancer [35, 36]. MiR-449a was also found to be down-regulated in NPC [20]. MiR-449a can directly target HDAC1 in primary lung cancer and inhibit cell growth and anchorage-independent growth [37]. Trichostatin A (TSA) could strongly increase miR-449a levels in testicular cancer cell lines and miR-449a down-regulated the histone deacetylase Sirt1 [38]. These studies manifest that miR-34c and miR-449a were regulated by the epigenetic factors. According to our previous data, miR-29c, miR-34c, miR-449a were down-regulated in NPC. In this study, we treated the NPC cell line HNE-1 and CNE-2 by 5-AzaCdR for 96 h and then found that miR-34c and miR-449a increased. MiR-34c and miR-449a were associated with cell proliferation, apoptosis, anti-tumor drug resistance and serum biomarkers of recurrence in other cancers, this new miRNA-miRNA pathway may provide a new sight on the diagnosis, treatment, and prognosis of NPC.

Conclusions
In a summary, we found that miR-29c was further confirmed to be down-regulated in NPC cell lines HNE-1, CNE2, C666-1 and tissues, and firstly reported that restoration of miR-29c increases the expression miR-34c and miR-449a which were regulated by DNA methytranferases through epigenetic factors. Our experiments verified that DNMT-3a and -3b are the targets of miR-29c. As epigenetic regulation is reversible, the effects can be available through specific drugs such as DNMT inhibitors (5-Aza-CdR) with or without HDAC inhibitor (TSA). Another kind of strategy, oligonucleotides (synthetic miRNA oligonucleotides) can be used directly in vivo to correct the disorders in miRNA expression levels, which is expected as a new therapeutic tool for the nasopharyngeal carcinoma patients.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MN, DG,QW, PW, SP (Suming Pan), HM carried out the molecular biological studies, CS, JX, ZL, SF carried out the immunoassays of the tissues, GL conceived of the study and coordination and designed the experiments, SP (Shuping Peng) drafted the manuscript and performed the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by Natural Science Foundation of China(81572577, 81372366, 81000882, 81472773), Program for New Century Excellent Talents in University (NCET-12-0544), overseas, Hong Kong & Macao Scholars Collaborated Researching Fund of National Natural Science Foundation of China (81428018), 111 project(111-2-12), national 863 plan (2012AA02A206), the Fundamental Research Funds for the Central Universities (2013ISJ046), The Hunan Province Natural Science Foundation of China(10J07003), the Open-End Fund for the Valuable and Precision Instruments of Central South University, and Innovation project for postgraduate of Central South University(2015szts278).

Author details
1. Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
2. Second Xiangya Hospital, Central South University, Changsha 410078, China.
3. Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
4. Guangdong Provincial Yuebei People’s Hospital, Shaoquan 512025, China.
5. Orthopedic Biomedical Materials Institute, Central South University, Changsha 410083, China.

Received: 18 May 2015 Accepted: 8 March 2016
Published online: 15 March 2016

References
1. Liu WL, Lin YH, Xiao H, Xiong S, Chen H, Chi PD, Zhang G. Epstein-Bar virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions. J Virol. 2014;88(12):6660–71. 2. Yip YL, Pang PS, Deng W, Tsang CM, Zeng M, Hau PM, Man C, Jin Y, Yuen AP, Tsao SW. Efficient immortalization of primary nasopharyngeal epithelial cells for EBV infection study. PLoS One. 2013;8(10), e78995. 3. Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J. Cancer. 2011;30(4):231–9. 4. Yang X, Dai W, Kwong DL, Szeto CY, Wong EH, Ng WT, Lee AW, Ngu RK, Yau CC, Tung SY, Lung ML. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer. 2015;136(4):E127–35. 5. Ayadi W, Allaya N, Frikha H, Trigui E, Khabir A, Ghorbel A, Daoud J, Frikha M, Gargouri A, Mokdad-Gargouri R. Identification of a novel methylated gene in nasopharyngeal carcinoma: TTC40. Biomed Res Int. 2014:2014:691742. 6. Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y, Liu Y. Genome-wide analyses of radiosensitivity-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. PLoS One. 2013;8(12), e84486. 7. Yu H, Liu J, Zuo L, Yan Q, Yu Z, Li X, Huang J, Zhao L, Tang H, Luo Z, Liao Q, Zeng Z, Zhang J, Li G. Epstein-Bar virus downregulates microRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J Virol. 2012;86(6):3088–99. 8. Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J, Thorley-Lawson DA. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol. 2009;83(5):3537–67. 9. Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, Zhou Y, Zhou M, Zeng Z, Li X, Shen S, Shuai C, Li G, Fang J, Peng S. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 2012;7(10),e46367. 10. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng RX, Zeng YY, Xie D, Mai SJ. MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett. 2013;329(1):91–8. 11. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, He QM, Jiang W, Ma J. MiR-29c suppresses invasion and metastasis by targeting TIA1 in nasopharyngeal carcinoma. Cancer Lett. 2013;329(2):181–8. 12. Sengupta S, den Boon JA, Chen H, Newton MA, Stahrope SA, Cheng YJ, Chen CJ, Hildeheim A, Sugden B, Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating miRNAs encoding extracellular matrix proteins. Proc Nate Acad Sci USA. 2008;105(15):5874–8. 13. Zhang XM, Wang XY, Sheng SR, Wang JR, Li J, et al. Expression of tumor related genesNGX6, NAG-7, BRD7, and its deletion mutants in the proliferation, adhesion and migration of nasopharyngeal carcinoma 5-8F cells. Oncology. 2006;73(1–2):273–81.
16. Mao YP, Li WF, Chen L, Sun Y, Liu LZ, Tang LL, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1022–8.

17. Sun Y, Ma J. Comment for the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng. 2009;28(10):1016–21.

18. Luo Z, Zhang L, Li Z, Li X, Li G, Yu H, Jiang C, Dai Y, Guo X, Xiang J, Li G. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012;5:3.

19. Li G, Qu Y, Su Z, Ren S, Liu C, Tian Y, Liu Y. Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. PLoS One. 2013;8(12):e84486.

20. Ti HL, Nong L, Wang W, Zhang S, Li T. Expression of microRNA in extranodal NK/T cell lymphoma, nasal type. Zhonghua Bing Li Xue Za Zhi. 2011;40(9):610–5.

21. Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen KH, Li Y. microRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep. 2011;25(5):1353–63.

22. Corney DC, Hwang CI, Matoso A, Vogt M, Fleksen-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16(4):1119–28.

23. Gallardo E, Navarro A, Vőlias N, Marrades RM, Díaz T, Gel B, Quera A, Bändres E, García-Fonzillas J, Ramírez J, Monzo M. miR-34a as a prognostic marker of relapse in surgically resected non-small cell lung cancer. Carcinogenesis. 2009;30(11):1903–9.

24. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–9.

25. Tanaka N, Toyooka S, Soh J, Kubo T, Yamanoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer. 2012;76(1):32–8.

26. Bork S, Horn P, Castoldi M, Hellwig I, Ho AD, Wagner W. Adipogenic differentiation of human mesenchymal stromal cells is down-regulated by microRNA-369-Sp and up-regulated by microRNA-371. J Cell Physiol. 2011;226(9):2284–9.

27. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2011;6(3):388–94.

28. Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X, Liu Y, He Y, Park EY, Zhang H, Lu X, Ma K, Su F, Park JH, Song E. MicroRNA-34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem. 2012;287(1):465–73.

29. Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-Sp determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71:1159–71.

30. Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F, Tan X, Lu NS, Sun J, Sun N. He J. DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol Ther. 2011;11:490–6.

31. Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, Choi E, Na MJ, Park JY, Xiang J, Son JW. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer. 2012;76:171–6.

32. Lizé M, Pilarski S, Dobbelstein M. EZF1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2010;17:452–8.